Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells

Laboratory Investigation

Volumn 84, Issue 8, 2004, Pages 1050-1059

  Murata, Hiroaki ^a   Tsuji, Shingo ^a   Tsujii, Masahiko ^a   Sakaguchi, Yasuko ^a   Fu, Hai Ying ^a   Kawano, Sunao ^a,b   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

5 aza 2 deoxycytidine; Cell growth; COX 2; HCC; Hypermethylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELECOXIB; CYCLOOXYGENASE 2; DEOXYCYTIDINE; PROSTAGLANDIN E2;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN; CELL STRAIN FLC 7; CELL STRAIN HEP3B; CELL STRAIN HEPG2; CELL STRAIN HUH7; CELL STRAIN PLC; CELL STRAIN SK HEP1; CONTROLLED STUDY; DEMETHYLATION; DOSE RESPONSE; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HYPOTHESIS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; UPREGULATION;

AZACITIDINE; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; DINOPROSTONE; DNA METHYLATION; DNA, NEOPLASM; GENE SILENCING; HUMANS; ISOENZYMES; LIVER NEOPLASMS; MEMBRANE PROTEINS; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 3543100257     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700118     Document Type: Article

References (69)

1. Jones PA, Laird PW. Cancer epigenetics comes of age. Nature Genet 1999;21:163-167.
2. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-146.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
4. Wutz A, Smrzka OW, Schweifer N, et al. Imprinted expression of the Igf2r gene depends on an intronic CpG island. Nature 1997;389:745-749.
5. Stögert RP, Kubicka P, Liu CG, et al. Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal. Cell 1993;73:61-71.
6. Counts JL, Goodman JI. Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 1995;83:13-15.
7. Warnecke PM, Bestor TH. Cytosine methylation and human cancer. Curr Opin Oncol 2000;12:68-73.
8. Bird A. DNA methylation. Science (Wash DC) 1999; 286:2287-2288.
9. Jones PA. DNA methylation errors and cancer. Cancer Res 1996;56:2463-2467.
10. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-12872.
11. Maier JA, Hla T, Maciag T. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem 1990;265:10805-10808.
12. Inoue H, Yokoyama C, Hara S, et al. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. J Biol Chem 1995;270:24965-24971.
13. Ristimäki A, Garfinkel S, Wessendorf J, et al. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 1994;269:11769-11775.
14. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;197:1183-1188.
15. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451-455.
16. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinoma. Cancer Res 1998;58:2929-2934.
17. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:198-204.
18. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
19. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995;83:493-501.
20. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
21. Tsujii M, Kawano S, DuBois RN. cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94:3336-3340.
22. Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002;62:1567-1572.
23. Fantappiè O, Masini E, Sardi I, et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 2002;35:843-852.
24. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999; 29:688-696.
25. Rahman MA, Dhar DK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001;7:1325-1332.
26. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001;7:1410-1418.
27. Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterol 1999;46:407-412.
28. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999;5:4005-4012.
29. Cheng J, Imanishi H, Iijima H, et al. Expression of cyclooxygenase 2 and cytosoloic phospholipase A2 in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol Res 2002;23:185-195.
30. DuBois RN, Shao J, Tsujii M, et al. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996;56:733-737.
31. Trifan OC, Smith RM, Thompson BD, et al. Overexpression of cyclooxygenase-2 induces cell cycle arrest. J Biol Chem 1999;274:34141-34147.
32. Santoro MG, Philpott GW, Jaffe BM. Inhibition of tumour growth in vivo and in vitro by prostaglandin E. Nature 1976;263:777-779.
33. Prasad KN. Morphological differentiation induced by prostaglandin in mouse neuroblastoma cells in culture. Nat New Biol 1972;236:49-52.
34. Shimakura S, Boland CR. Eicosanoid production by the human gastric cancer cell line AGS and its relation to cell growth. Cancer Res 1992;52:1744-1749.
35. Nakamura A, Yamatani T, Fujita T, et al. Mechanism of inhibitory action of prostaglandins on the growth of human gastric carcinoma cell line KATO III. Gastroenterology 1991;101:910-918.
36. Derubertis FR, Craven PA, Saito R. 16, 16-dimethyl prostaglandin E2 suppresses the increases in the proliferative activity of rat colonic epithelium induced by indomethacin and aspirin. Gastroenterology 1985;89:1054-1063.
37. Craven PA, Saito R, Derubertis FR. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 1983;72:1365-1375.
38. Sheng H, Shao J, Washingon MK, et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-18081.
39. Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-293.
40. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. New Engl J Med 1991;325:1593-1596.
41. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. New Engl J Med 1995;333:609-614.
42. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-1327.
43. Toyota M, Shen L, Ohe-Toyota M, et al. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res 2000;60:4044-4048.
44. Song SH, Jong HS, Choi HH, et al. Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5′CpG island in human gastric carcinoma cells. Cancer Res 2001;61:4628-4635.
45. Akhtar M, Cheng Y, Romina M, et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 2001;61:2399-2403.
46. Shen L, Ahuja N, Shen Y, et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 2002;94:755-761.
47. Aden DP, Fogel A, Plotkin S, et al. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979;282:615-616.
48. Hsu IC, Tokiwa T, Bennett W, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993; 4:987-992.
49. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-811.
50. Takahashi M, Katayama Y, Takada H, et al. The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther 2000;14 (Suppl 1):44-49.
51. Bird AP. CpG-rich islands and the function of DNA methylation. Nature (London) 1986;321:209-213.
52. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196:261-282.
53. Lukiw WJ, Pelaez RP, Martinez J, et al. Budenoside epimer R or dexamethasone selectively inhibit platelet-activating factor-induced or interleukin 1beta-induced DNA binding activity of cis-acting transcription factors and cyclooxygenase-2 gene expression in human epidermal keratinocytes. Proc Natl Acad Sci USA 1998;95:3914-3919.
54. Inoue H, Nanayama T, Hara S, et al. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells. FEBS Lett 1994;350:51-54.
55. Yamamoto K, Arakawa T, Ueda N, et al. Transcriptional role of nuclear factor kappaB and nuclear factor-interluekin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995;270:31315-31320.
56. Clark SJ, Harrison J, Molloy PL. Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 1997;195:67-71.
57. Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 1991;251:186-189.
58. Asiedu CK, Scotto L, Assoian RK, et al. Binding of AP-1/CREB proteins and of MDBP to contiguous sites downstream of the human TGF-beta 1gene. Biochim Biophys Acta 1994;1219:55-63.
59. Kass SU, Pruss D, Wolff AP. How does DNA methylation repress transcription? Trends Genet 1997;13:444-449.
60. Bestor TH. Gene silencing. Methylation meets acetylation. Nature 1998;393:311-312.
61. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-8686.
62. Saito Y, Kanai Y, Sakamoto M, et al. Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci USA 2002;99:10060-10065.
63. Zhang YJ, Ahsan H, Chen Y, et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 2002;35:85-92.
64. Bakker J, Lin X, Nelson WG. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem 2002;277:22573-22580.
65. Zhong S, Tang MW, Yeo W, et al. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBVF-associated hepatocellular carcinomas. Clin Cancer Res 2002;8:1087-1092.
66. Tchou JC, Lin X, Freije D, et al. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int J Oncol 2000;16:663-676.
67. Schagdarsurengin U, Wilkens L, Steinemann D, et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003;22:1866-1871.
68. Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:247-257.
69. Kern MA, Schubert D, Sahi D, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002;36:885-894.